MENVEO
Brand Name: MENVEO
Composition: Meningococcal Group A, C, W135 and Y Conjugate Vaccine Ph. Eur.
Format: Powder and solution for injection
Administration: Intramuscular injection
Dose: 1 dose of 0.5 mL (reconstituted)
Product Description
Medical Info
MENVEO is a critical quadrivalent conjugate vaccine (Ph. Eur.) developed to defend against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W135, and Y. Presented as a powder and solution kit, it requires reconstitution immediately before use by combining one vial of MenA Lyophilized Conjugate Component with one vial of MenCWY Liquid Conjugate Component. Once mixed, a single 0.5 mL dose is administered via deep intramuscular injection, providing broad and effective immunity. MENVEO is used globally in adolescent and adult populations to prevent life-threatening meningitis and septicemia, forming a key component of routine vaccination and outbreak prevention strategies.
Storage & Safety
Precautions & Warnings
Reconstitute only with the prescribed quantity of clean drinking water. Shake well before each use. Complete the full course as prescribed. Discard any unused suspension after 7 days of reconstitution.
Storage
Store in a cool, dry place below 25°C. Protect from light and moisture. Refrigeration after reconstitution is preferred.
Status
Keep all medicines out of reach of children.
